A bewildering number of clinical studies on the efficacy of cytotoxic chemotherapy for various adult solid tumours has been reported. Enthusiasm among medical oncologists has been generated largely by the dramatic successes achieved by chemotherapy over the past 10 years in fairly uncommon malignancies, such as Hodgkin's disease, histiocytic lymphoma, germ cell tumours, choriocarcinoma, and various solid tumours of childhood. In addition, high rates of partial response are often achieved nowadays with combinations of cytotoxic drugs in several hitherto untreatable adult malignancies. The race to conquer cancer with drugs has been further intensified by the non-medical press and by energetic advertising programmes of pharmaceutical companies.
Despite the current wave of enthusiasm the vast majority of chemotherapy is given with palliative intent.' Thus a rational decision to use cytotoxic drugs must inevitably entail the often complex trade off between likely benefits and expected side effects (both physical and non-physical). The use of toxic, and therefore potentially fatal, cytotoxic drugs should be seriously questioned unless they are likely either to yield a high incidence of durable complete remissions (some leading to ultimate cure) or to cause such regression of advanced cancer that symptomatic relief affords a prolonged period of improved quality of life. Lamentably, however, not only is our ability to assess palliation and quality of life rather rudimentary but the current proliferation of trial results that cannot be properly evaluated (see below) may lead both oncologists and non-oncologists to overestimate the role of chemotherapy and, at the same time, to undervalue the impact of toxicity related to treatment. The problem is compounded by recent technological innovations and a current vogue for intensive investigations to characterise the malignancy accurately in terms of its biological behaviour and extent of spread. Such intensive investigation is often inappropriate to the patient's needs and makes it extremely difficult for the clinician not to "do something," even though he may know enough to appreciate that active treatment might well do more harm than good.
Lack of space precludes a discussion of all adult solid tumours, but I have examined here the current impact that cytotoxic chemotherapy is having in the treatment of the most common adult malignancies. To suggest reasonable recommendations on the role of cytotoxic drugs and to define subsets of patients most likely to derive benefit from such treatment I have emphasised those studies from which meaningful conclusions can be drawn.
Problems of partial response
Antitumour efficacy has been defined primarily in terms of some measurable reduction in the patient's total tumour burden. Many methods have been used to assess regression of tumour, which has been defined in several different ways. Indeed, subtle differences in the criteria for response cause large changes in apparent response rates. Tonkin et al expressed their concern about the wide disparity in reported rates of tumour response when patients with the same type of tumour are treated with similar cytotoxic regimens.2 Indeed, serious methodological inaccuracies (including use of uncontrolled studies, small numbers of patients, varying cytotoxic doses and schedules, and inconsistent criteria for response) often make conclusions about the merits of a particular regimen impossible, ambiguous, or even erroneous. 2 Except in the case of a few rare tumours in which specific biological markers accurately reflect tumour burden, clinicians must For common sites the numbers predicted were: lung 144 000 (15-8%), colorectal 134 000(14 7%), breast 119 000 (13-1%), prostate 86 000 (9-5%), head and neck 58 000 (6.4%), bladder 40 000 (4 4%), endometrium 37 000 (4 10%), and pancreas 25 000 (2 7%). These eight major malignancies would account for 70% of the total incidence of cancer and 66% of the total mortality from cancer.
The review below provides a critical summary of the current state of cytotoxic chemotherapy in the treatment of these common adult malig- To determine whether fluorouracil is superior when given intra-arterially rather than systemically the Central Oncology Group embarked on a prospective controlled clinical trial comparing these two methods in 61 patients.27 Though the response rate for the intra-arterial infusion arm was slightly higher than that for the systemic arm, the difference was not significant. The intra-arterial infusion arm was associated with a greater incidence of nausea, vomiting, and diarrhoea in addition to the complications of arterial thrombosis, bleeding, and infection at the site of the catheter. optimistic view from well designed trials is that an improvement in relapse free survival at five years of 10-20% may occur in selected subsets of women with positive axillary nodes; the benefit in terms of overall survival is even less.
In October 1984 representatives of almost all the organisations that had conducted randomised controlled trials of adjuvant cytotoxic therapy in early breast cancer met to determine whether there was any evidence that such treatment influences patient survival. An analysis of data from 37 controlled trials indicated that among women with early breast cancer there was a clearly significant reduction in short term mortality.32 For instance, the net effects of cytotoxic therapy on early mortality among all treated women was a 24% reduction in "odds of death." For patients aged under 50 at diagnosis the reduction in odds of death was 36%.
Although these preliminary analyses achieved a high degree of statistical significance, there is some uncertainty among clinicians about the clinical interpretation and implications of the crude statistics, specifically the term "reduction in odds of death." It would obviously be misleading of clinicians to equate reduction in odds ofdeath with reduction in mortality. In addition, whether these claimed reductions in early mortality will have long term benefit awaits future confirmation.
Unfortunately, early survival figures and data on the short term reduction in absolute mortality failed to provide sufficient evidence on which to assess the value of adjuvant chemotherapy. No study has yet addressed the all important question ofwhether adjuvant treatment offers any survival benefit over reserving the same adjuvant cytotoxics for the treatment of symptomatic secondary deposits. Coburn four weeks. Any appreciable responses will occur within six weeks of the start of treatment; most remissions, however, are only partial and will persist for four to five months. 54 Combinations of the four single agents mentioned above have been sufficiently studied to permit several general conclusions. Rates of response to combination regimens are generally slightly higher than those to single agents. 54 Regimens containing doxorubicin without cisplatin are no more effective than doxorubicin alone.53 There is some evidence that cisplatin and doxorubicin, with or without cyclophosphamide, may be more active than cisplatin alone.5' However, few trials have been randomised and the widely varying response rates obtained with combination regimens, with complete responses of less than 10%, make it questionable whether combination regimens confer any appreciable benefit over cisplatin alone, especially in view of the considerable morbidity experienced by patients, who are generally elderly. Sternberg et al reported a 77% response rate with a combination of methotrexate, vincristine, doxorubicin, and cisplatin.56 Despite this promising result, however, it remains unproved whether chemotherapy can reliably offer clinically useful palliation or useful extension of survival for the vast majority ofpatients with metastatic bladder cancer.
There has been recent enthusiasm for induction chemotherapy, given before definitive treatment of locally advanced disease with either radical surgery or radiotherapy. Raghavan et al reported their results in 50 patients with invasive, high risk bladder cancer treated initially with cisplatin 100 mg/m2 intravenously in two doses with a three week interval before definitive treatment.57 Major symptomatic improvement was noted in 76% ofpatients, and 60% had an objective response. The 12 month actuarial survival was 86% and the two year actuarial survival 80%. Although similar early, promising results from several pilot studies are being reported,58 this approach must still be regarded as experimental.
ENDOMETRIAL CANCER
Experience with cytotoxic chemotherapy in endometrial cancer is limited because of the efficacy of surgery with or without radiotherapy and the sensitivity of the disease to progestogen. For palliation of advanced disease resistant to hormones, however, cytotoxic drugs are only modestly effective. Of the many single agents studied, doxorubicin and cisplatin seem to yield the highest response rates.59 Combinations of doxorubicin and cisplatin in small groups of patients have yielded conflicting response rates, varying between 33% and 82%." 61 Though some authors claim that the combination of doxorubicin and cisplatin is superior to all other regimens for advanced endometrial carcinoma,6' others have found that it yields similar response rates and durations of survival to either agent used singly, but at the cost of considerable additional morbidity.' PANCREATIC CANCER Despite some initial promising objective responses with cytotoxic combinations such as fluorouracil/doxorubicin/mitomycin C and streptozotocin/mitomycin C/fluorouracil recent studies continue to confirm the chemoresistance of pancreatic cancer.62 Neither single drugs nor combination regimens achieve complete response rates greater than 5%, and, of these, less than 10% last one year. In a critical review O'Connell concluded that no form of current chemotherapy has been shown to offer consistently worthwhile benefit to patients with advanced pancreatic cancer,63 and chemotherapy may well be contraindicated in view of its toxicity, expense, and lack of demonstrable survival advantage. Instead 38 000.? "Thus," he concluded, "the majority of the patients exposed to chemotherapy will have most of the side effects and little of the benefit."" The numerical impact of chemotherapy in adult solid tumours will be even smaller than the above estimates suggest when the influence of chemotherapy on many curable malignancies of childhood is excluded.
The popular notion that five year survival can be equated with cure is clearly of limited value because of its inability to take into account the great variations in the clinical course of different tumours. For example, carcinomas of the breast and prostate are notorious for late recurrence, occasionally well over five years after definitive local treatment. There is also controversy over how well recent improvements in five year survival rates actually reflect improved treatment.65 Earlier diagnosis and treatment of cancer as a consequence of mass screening and new technology, changing diagnostic criteria, and changes in the way cancers are recorded and registered are additional important variables that have a net positive influence on survival statistics. Although dramatic advances have occurred in the treatment and survival of patients with fairly rare cancers, several eminent workers now believe that the much publicised recent gains in five year survival (and "cure") are more apparent than real.65 3 Conclusions and recommendations for the future Treatment of the most common adult tumours by cytotoxic chemotherapy is still disappointing. The current plethora ofclinical papers does little to recommend the routine use ofcytotoxic drugs in the treatment ofnon-small cell lung cancer and colorectal, prostatic, and head and neck cancers. Even in small cell lung cancer, in which cytotoxic drugs have dramatically improved median survival over that in untreated patients, toxicity is considerable and five year survival only 5-8% at best. The adjuvant use of cytotoxic drugs for "early" breast cancer remains highly contentious; for advanced disease, however, judicious use will occasionally provide long periods of clinically useful palliation. As Mead and Whitehouse recently concluded, "for most patients with advanced solid tumours, chemotherapy is not indicated as a routine practice."5 What comments and recommendations can be made for the future? Firstly, reliable criteria for assessing both tumour response and palliation (quality of life) are required. Perhaps, for instance, linear analogue selfassessment scores could be incorporated into the assessment of how well stated therapeutic goals are achieved.6' Improvement in these objective measures would go a long way towards allowing non-productive, costly, and often toxic cytotoxic regimens to be recognised and discarded.
Secondly, there is a need for better designed clinical trials and a less pragmatic approach to the use of cytotoxic drugs. Controlled, randomised prospective clinical trials most definitely and accurately test new therapeutic regimens. Small, uncontrolled studies with small numbers of patients too often produce non-definitive, ambiguous results. Though phase II and pilot studies may offer clues for future treatments, their results must not be used as a basis for modifying current therapeutic successes of surgery and radiotherapy without confirmation in controlled studies. Surgery and radiotherapy still remain the only proved curative treatments for common solid malignancies in adults.
Thirdly, and a byproduct of properly conducted clinical studies, is the identification of subgroups of patients most likely to benefit from a given cytotoxic regimen. The management of advanced cancer remains a palliative exercise, and physicians need to become -more sensitive to the need to tailor treatment to individual patients on the basis of factors related to both the patient and his disease.
Fourthly, we simply need newer cytotoxic agents with a more favourable therapeutic ratio. Chabner etal stated that "only through the discovery of significant new agents (such as interferons, lymphokines or monoclonal antibodies) will it be possible to produce durable responses and cures in the majority of patients" to eventually displace conventional cytotoxic drugs. 67 Fifthly, there are lessons to be learnt by those in charge oftraining in oncology. Despite the disappointing performance of conventional chemotherapy in the treatment of many common solid tumours, cytotoxic drugs are being used more and more and in an uncontrolled fashion. Though such modest advances as have occurred are a stimulus for future study, they hardly justify the massive proliferation oftraining posts in oncology and the elevation of the specialty to "superstar" ranks, as has occurred in the United States. Medical oncologists have played, and will continue to play, an important part in basic scientific and clinical research as well as in the education ofmedical and lay staff. Clearly there is still a need for a limited number of pure medical oncologists to pursue basic laboratory and clinical research in large cancer centres. It would seem most cost effective, however, to train doctors to be able to work as radiotherapists as well as medical oncologists so that they may be employed to act as cancer specialists at the level of the district general hospital.
Finally, cost considerations may necessitate a more reasoned and limited approach to the use of cytotoxic drugs in the future. In a detailed analysis of the costs of cancer treatment at Peter MacCallum Hospital, Melbourne, Ilbery contrasted the high annual cost ofcytotoxic chemotherapy with the considerably lower costs of megavoltage radiotherapy." 8 Milsted et al assessed the financial cost of cancer chemotherapy over 20 months during 1978-9 to be $212 000 (or 9-3% of a major teaching hospital's total pharmacy budget for that period).'9 This, taken together with a median survival for patients given palliative treatment ofroughly 40 weeks, led to the conclusion that "the widespread use of cancer chemotherapy is not justified outside well conducted clinical trials or specialist cancer centres." Recently, Tattersall went further in stating that "it can be argued that cancer chemotherapy should not be made available widely in the community because of its limited efficacy and significant morbidity."7" I hope that the major aspects of current chemotherapy for cancer raised here will lend support to such an argument.
Is the natural history ofClostridium tetani such that protective levels ofimmunity might be maintained in those-for example, gardeners and builders-who by the nature oftheir work are continually suffering minor lacerations. How ubiquitous is the organism in its active and latentforms? Is there any good evidence that active immunisation should be atfive rather than 10year intervals?
Tetanus is due to the production of toxin by Clostridium tetani under the anaerobic conditions present in wounds. Even those who have recovered from tetanus do not gain reliable immunity and active immunisation is therefore essential especially for those continually suffering minor lacerations that may be contaminated. The organism is widespread in soil contaminated with animal excreta (including wild animals) making, for example, football pitches a source of infection as well as domestic gardens and fields grazed by farm animals. A full basic course of adsorbed vaccine (three "primary" doses in infancy followed by a preschool and teenage booster) induces durable immunity. Following this, in Britain, it is currently recommended that further reinforcing boosters should be given after injuries but not normally more frequently than every five years, unless the wound is particularly dirty, deep, or likely to have been contaminated. Whether routine reinforcing doses are needed for adults in other circumstances is debatable but many cases of tetanus occur without a history of preceding injury. It would seem reasonable therefore that especially those with occupational or other increased risks of infection should receive boosters at around 10 year intervals. The precise timing of boosters required to maintain protective antitoxin levels is likely to vary with individuals and it is better to be "safe than sorry."-ERIC WALKER, lecturer in infectious diseases, Glasgow. 
Correction
Use and misuse of a digoxin assay service We regret that an error occurred in this article by Dr Ian Gibb and others (13 September, p 678). In the abstract it was stated that "Treatment in 64 patients (22%) was changed either while awaiting the assay result or after receiving it...." This should have read "Treatment in 64 patients (22%) was changed after the assay result was received."
